DBV Technologies | DBVT - Current Liabilities


DBV Technologies reported $58.02M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amarin USD 179.64M 14.82M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
DBV Technologies USD 58.02M 8.54M Dec/2025
Esperion Therapeutics USD 300.36M 451K Mar/2026
Galectin Therapeutics USD 14.62M 1.98M Jun/2024
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026